Xintian Pharma released its performance for the first half of the year, with a net profit attributable to the parent company of 5.7661 million yuan, a decrease of 80.99%
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Xintian Pharma released its semi-annual report for 2025, reporting an operating income of 358 million yuan, a year-on-year decrease of 18.88%. The net profit attributable to shareholders of the listed company was 5.7661 million yuan, a year-on-year decrease of 80.99%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 3.5795 million yuan, a year-on-year decrease of 87.87%. The basic earnings per share were 0.0236 yuan
According to the Zhitong Finance APP, Xintian Pharma (002873.SZ) released its semi-annual report for 2025, showing an operating income of 358 million yuan, a year-on-year decrease of 18.88%. The net profit attributable to shareholders of the listed company was 5.7661 million yuan, a year-on-year decrease of 80.99%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 3.5795 million yuan, a year-on-year decrease of 87.87%. The basic earnings per share were 0.0236 yuan